Information Provided By: 
Fly News Breaks for October 16, 2019
EVFM
Oct 16, 2019 | 06:39 EDT
Cantor Fitzgerald analyst Louise Chen assumed coverage of Evofem with an Overweight rating and $9 price target. The market opportunity for the company's Amphora is underappreciated, Chen tells investors in a research note. Amphora could be: a first-in-class hormone-free birth control that also improves sexual satisfaction, says the analyst. She believes now is a good time to take another look at Evofem shares ahead of the Phase 2b trial results in November.
News For EVFM From the Last 2 Days
There are no results for your query EVFM
